openPR Logo
Press release

Global Anxiety Disorders Treatment to Witness Sustainable Growth: In-depth Industry Analysis with Key Player’s Strategic Movement; Eli Lily & Company, AstraZeneca, Pfizer, and GlaxoSmithKline

09-28-2018 06:02 PM CET | Health & Medicine

Press release from: AnalystView Market Insights

Global Anxiety Disorders Treatment to Witness Sustainable

AnalystView Market Insights has announced the addition of the “Global Anxiety Disorders Treatment Market Industry Analysis and Opportunity Assessment 2014 – 2025”. The global market is expected to grow at growth rate of 2.2% to reach USD 18,234 million by 2025.
The report analyzes the industry in terms of drug category, therapy and geography. This comprehensive study reveals the market estimate numbers for different market segments. Key industry dynamics, regulatory scenario, patent expiry of blockbuster drugs and strategic benchmarking and thorough competitive landscaping are discussed, spreading over 100 pages.

According to the World Health Organization (WHO), depression is the second-leading cause of disabilities, affecting more than 300 million populations across the globe. Thus, increasing prevalence of anxiety disorders such as depression has boosted the demand for effective treatment options, augmenting the market growth. Furthermore, raising awareness campaigns regarding anxiety disorders by the government or non-government bodies drive the industry growth. For instance, Anxiety and Depression Association of America (ADAA) started initiative named “BreaktheStigma”. This initiative is focused on raising awareness about anxiety and depression. Other factors such as new product developments and a growing number of companies investing in this market augment the growth significantly. However, patent expiry of major drugs has slow down the industry development since the last couple of years. For instance, Eli Lilly’s duloxetine delayed-release capsule (i.e. Cymbalta) for depression treatment has lost patent exclusivity in 2014. Owing to this, the revenue was declined significantly during the same period. In 2014, the company posted USD 1,614.7 million sales from Cymbalta, around 63% decrease compared to the previous year (USD 5,084.4 in 2014).

To request free sample copy:
www.analystviewmarketinsights.com/request_sample/av125/

Key Takeaways:
- Of the drug category, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Serotonin Reuptake Inhibitors (SSRIs) achieved the highest revenue share. In 2017, these segments recorded more than 60% revenue share collectively. The boost in demand for anxiety therapeutics coupled with the rising in a number of companies investing to develop new anxiety drugs drives the market revenue.
- The study further includes a detailed analysis of top-selling anxiety therapeutics such as Abilify, Cymbalta, Lyrica, Vyvanse among others.
- On contrary, anxiety therapies are growing with the highest CAGR of 3.7% owing to high efficiency in treating anxiety-related disorders and rising demand in developed regions such as North America and Europe
- Of the different therapies, Transcranial Magnetic Stimulator and Fischer Wallace Stimulator are the largest revenue-generating segment, recorded over USD 1,500 million revenue collectively throughout the study period. - In terms of indications, Major Depressive Disorder (MDD), and Obsessive-Compulsive Disorder (OCD) amounted to the largest revenue generating segment. MDD indicative anxiety problem is one of the highest affected condition among the young population.
- The industry is fragmented in nature. Companies such as Eli Lily and Company, Pfizer, Inc., AstraZeneca plc, H. Lundbeck and GlaxoSmithKline plc are leading players in this industry, accounted for more than 60% share of the global market revenue.
- Strategic initiatives to expand their presence in developing regions coupled with a huge investment in research activities to develop effective therapeutics or therapies helped these players to sustain in this market.
- For instance, in September 2016, Pfizer, Inc. introduced “Moodivator” app to help encourage, motivate and support people with depression. This app includes simple features such as goal setting and mood tracking that leverage best principle in managing depression

Browse full report with in-depth ToC on “Anxiety Disorders Treatment Market, By Drug Category (SSRIs, TCAs, SNRIs, MAOIs, Anticonvulsants, and Others), By Therapy (TMS, ECT, CBT, and FWS), and Geography (NA, EU, APAC, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025” at
www.analystviewmarketinsights.com/report-highlight-anxiety-disorders-treatment-market-125/

Scope of the Report:
Market, by Drug Category: Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants (TCAs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Monoamine oxidase inhibitors (MAOIs) and Anticonvulsants

Market, by Therapy: Transcranial Magnetic Stimulator, Electroconvulsive Therapy (ECT), Cognitive Behaviour Therapy (CBT) and Fischer Wallace Stimulator

Market, by Region: North America, Europe, Asia Pacific, Latin America, Middle East and Africa and Rest of the World; Market, by Country: U.S., Canada, Germany, France, India, and China;

Key players profiled in this report with special attention on competitive landscape includes, (can be further customized to include additional 10 profiles of companies):
Eli Lily & Company
Bristol-Myers Squibb Company
AstraZeneca plc
Johnson & Johnson
GlaxoSmithKline
Pfizer, Inc.

Key benefits of the report:
• The report presents a macro and micro-level outlook regarding the industry. Thus, it becomes easy for our clients to perceive the business landscape and take a glimpse of their own standing in it.
• A thorough analysis of relevant statistical data to estimate the market paradigms
• Exceptional understanding of region and country-specific markets. The report will answer some of the toughest questions regarding the market shares, sizes, forecasts segmentations, and growth specific to the countries.
• Well-designed strategic framework analyzes the market movements including regional expansion, mergers & acquisitions, and new product developments

Find out more by getting in touch: https://www.analystviewmarketinsights.com/get-in-touch/

About AnalystView Market Insights
AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends for various industries such as Healthcare, Bulk Chemicals, Semiconductors, Electronics, and Foods and Beverages.

Contact us for more details:
Mr. Jose (Press & Marketing Manager)
Corporate Sales, USA
AnalystView Market Insights
Email: sales@analystviewmarketinsights.com
Tel: +91-757-498-5725 (Asia-Pacific Business Centre)
Web: www.analystviewmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Anxiety Disorders Treatment to Witness Sustainable Growth: In-depth Industry Analysis with Key Player’s Strategic Movement; Eli Lily & Company, AstraZeneca, Pfizer, and GlaxoSmithKline here

News-ID: 1270701 • Views:

More Releases from AnalystView Market Insights

Electric Vehicle Charging Stations Market : New Developments helps to grow market opportunities & forecast until 2026
Electric Vehicle Charging Stations Market : New Developments helps to grow marke …
According to latest study by AnalystView Market Insights provides the current status, and projected growth over the next five to ten years. Key topics addressed include market dynamics of the global Electric Vehicle Charging Stations market, projected industry revenue, average product pricing, among others.  With industry-standard accuracy in analysis and high data integrity, the reports from AnalystView Market Insights make a brilliant attempt to unveil key opportunities available to help
Radio Frequency Identification Technology Market Size, Share, Trend, Opportunity Assessment and Global Forecast to 2025 | Top Key Players; Atmel, Accenture and 3M
Radio Frequency Identification Technology Market Size, Share, Trend, Opportunity …
AnalystView Market Insights recently introduced an in-depth study on Global Radio Frequency Identification Technology market, describing different products and application area which elaborates market outlook and status to 2025. According to this study, by the end of 2025, the global Radio Frequency Identification Technology market is anticipated to reach USD 41.6 billion, growing at the growth rate of 15.1%. This proposed study provides a comprehensive analysis of radio frequency identification technology
Proteomics Market Research Report; Explores Market Trends, Size and Future Growth Prospect Until 2025
Proteomics Market Research Report; Explores Market Trends, Size and Future Growt …
New in-depth comprehensive study on “Global Proteomics Market” report has been added AnalystView’s report store. The report aims to describe about different products, application and technology which elaborates market outlook and status to 2025. According to this study, the global Proteomics market is expected to grow at growth rate of 10.2% to reach USD 25.3 billion by 2025.This proposed study provides comprehensive analysis based on industry’s growth potential, market drivers, barriers,
Global Industrial Robotics Market: Articulated Robots Continue to Hold a Major Share of Industry Revenue
Global Industrial Robotics Market: Articulated Robots Continue to Hold a Major S …
According to this study, Industrial Robotics market size to keep up the strong yearly development rate of 5.3% from USD 32.7 billion in 2017 to 2025. Trust that in the following couple of years, the industry’s showcase size will be extended, we expect that the market size will achieve 49.8 billion by the end of 2025. This industry analysis is a cumulative effort of paid primary interviews through paid data

All 5 Releases


More Releases for Disorder

Anti-Depressant Drugs Market to 2027 - Global Analysis and Forecasts By Depressi …
Anti-depressant drugs is a class of medications which is used to treat major depressive disorder, some anxiety disorders, some chronic pain conditions, and to help manage some addictions. Anti-depressant drugs also reduce symptoms of depressive disorders by correcting chemical imbalances of neurotransmitters in the brain. Chemical imbalances may be responsible for changes in mood and behavior. Anti-depressant drugs market is anticipated to grow in the forecast period owing to driving factors
Antidepressant Drugs Market Report 2018: Segmentation by Depressive Disorder (Ma …
Global Antidepressant Drugs market research report provides company profile for Alkermes Plc, Allergan Plc, Bristol Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd. and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms
Autism Spectrum Disorder (ASD) Treatment Market Report 2018: Segmentation by Aut …
Global Autism Spectrum Disorder (ASD) Treatment market research report provides company profile for Roche Pharmaceuticals, Autism Treatment Plus, Fraser, Retrophin, Inc., Autism Services Inc., Pfizer Inc., SynapDx, Behavior Analysis, Inc., Autism Therapeutics, Curemark LLC and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate,
Speech Therapy Service Market Report 2018: Segmentation by Product (Speech Disor …
Global Speech Therapy Service market research report provides company profile for Benchmark Therapies, Talk Speech, Language Therapy, Speech Plus, Smart Speech Therapy, Therapy Solutions, Glenda Browne Speech Pathology and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018
Somatostatin Receptor Market For Hormonal Disorder, Oncology, Metabolic Disorder
MarketResearchReports.Biz adds “Global Somatostatin Receptor Market Share, Size, Trends and Forecast Market Research Report” reports to its database. This report provides a strategic analysis of the Somatostatin Receptor and the growth estimates for the forecasted period. This report studies the Somatostatin Receptor Type 2 market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global
Thyroid Gland Disorder Treatment Market: Increasing incidence of Autoimmune Dise …
The global market for thyroid gland disorders features a consolidated vendor landscape with a handful of companies accounting for a major chunk of the global market, observes Transparency Market Research in a recent report. In 2016, the thyroid gland disorders treatment market was dominated by Merck KGaA and AbbVie, Inc., which collectively accounted for more than half of the market. It has been observed that despite the large pool of